Lowering nicotine in smoked tobacco products in New Zealand
Assessing the real-world impact of a low nicotine product standard for smoked tobacco in New Zealand
This project looks at how cutting nicotine in cigarettes affects adults who smoke daily in New Zealand over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project ID | NIH-11382647 on NIH RePORTER |
What this research studies
You would join a group of about 1,500 adults who smoke daily or nearly daily and be followed across the period around a national nicotine-lowering policy. You'll complete online surveys, give biological samples for exposure biomarkers, have basic health measurements, and take part in interviews about your experiences. The team will also review medical records to track health and quit attempts. The study uses these mixed methods to see how smoking behavior, exposure, and well-being change before and after the policy.
Who could benefit from this research
Good fit: Adults (21 years or older) who smoke daily or nearly daily and live in New Zealand, and who are willing to complete surveys, provide samples, and share health records, are the ideal participants.
Not a fit: People who do not smoke, who smoke only occasionally, are under 21, or live outside New Zealand would not be eligible or likely to benefit directly from participating.
Why it matters
Potential benefit: If successful, this work could show whether lowering nicotine in smoked tobacco leads to less smoking, lower toxic exposure, and more quitting, supporting policies that protect smokers' health.
How similar studies have performed: Randomized trials of very low nicotine cigarettes have shown reduced smoking and dependence, but national, real-world effects under a mandated product standard are largely untested.
Where this research is happening
Winston-Salem, United States
- Wake Forest University Health Sciences — Winston-Salem, United States (Active)
Researchers
- Principal investigator: Denlinger-Apte, Rachel — Wake Forest University Health Sciences
- Study coordinator: Denlinger-Apte, Rachel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.